BioCentury
ARTICLE | Clinical News

Humanized SMART anti-Tac antibody that blocks interleukin-2 binding to activated T cells: Licensee Hoffmann-La Roche has treated the final patients in the Phase

January 9, 1995 8:00 AM UTC

Protein Design Labs Inc. (PDLI), Mountain View, Calif. Product: Humanized SMART anti-Tac antibody that blocks interleukin-2 binding to activated T cells Indication: Prevent graft-versus-host disease a...